Hemocompatibility of drug-eluting coronary stents coated with sulfonated poly (styrene-block-isobutylene-block-styrene)
Department of Cardiology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. Biomaterials
(Impact Factor: 8.56).
08/2012; 33(33):8204-12. DOI: 10.1016/j.biomaterials.2012.07.066
The presence of polymer coating on a coronary stent is a major mediator of coronary inflammation reaction thereby affects re-endothelialization. Poly(styrene-block-isobutylene-block-styrene) (SIBS) is one of the most attractive alternatives to serve as stent coating, but has shown less than optimal biocompatibility. Increasing the sulfonic acid content in the polymer can result in increased strength and hydrophilicity. The present study was undertaken to determine the mechanism of action and in vivo efficacy of sulfonated SIBS (S-SIBS) designed specifically as a stent polymer with reduced inflammatory potential and greater endothelialization preservation potential. The blood compatibility of S-SIBS in vitro and its ability to support the attachment of human umbilical vein endothelial cells (HUVECs) were first assessed to get some insight into its potential use in vivo. Baer metal stent (BMS), S-SIBS-coated stent without drug (BMS Plus S-SIBS), standard drug-eluting stent (DES) and S-SIBS-coated drug-eluting stent (DES Plus S-SIBS) were then implanted in the coronary arteries of a porcine model. Neointimal hyperplasia was evaluated at 28 and 180 days, and re-endothelialization was evaluated at 7 and 28 days post stents implantation. The results showed that DES Plus S-SIBS exhibited similar ability to reduce neointimal hyperplasia but preserved endothelialization compared with standard DES. These results suggest potentially promising performance of S-SIBS-coated stent in human clinical applications of coronary stenting.
Available from: content.iospress.com
- "An experienced pathologist blinded to the treatment groups performed all histological analyses. Ordinal data including injury and inflammation scores, neointimal thickness and area, percent lumenal stenosis, lumen area, and internal elastic membrane area were collected on each stent section according to previously reported methods  "
[Show abstract] [Hide abstract]
Drug-eluting balloons (DEB) may be promising technology for treating atherosclerotic arterial disease. In fact, several DEBs have been clinically available for the treatment of coronary in-stent restenosis (ISR), de novo coronary lesions, and peripheral artery disease.
We sought to elucidate the mechanism of action and in vivo safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon.
In vitro cytotoxicity of a novel DEB on human umbilical vein endothelial cells (HUVECs) and in vivo pharmacokinetics of DEB in a rabbit aorta abdominalis were assessed. Then, bare metal stents (BMS) were implanted at both the proximal and distal sites of the rabbit aorta abdominalis. Stented vascular segments were immediately dilated with a bare balloon (control group) or the DEB (DEB group) randomly. Histological evaluation was performed in all treated segments at 28 days. Because paclitaxel is a tubulin-disrupting agent that binds preferentially to β-tubulin, we measured β-tubulin expression in aortal stent specimens via immunohistochemistry.
We observed that DEB was compatible and could reduce neointimal hyperplasia compared with the bare balloon. Meanwhile, immunohistochemistry revealed that β-tubulin expression in the DEB group increased compared with the control group, indirectly suggesting successful uptake of paclitaxel by vessel walls after DEB dilation.
The novel DEB is safe and has a favorable vascular healing response on neointimal hyperplasia.
Available from: Jing Jin
[Show abstract] [Hide abstract]
ABSTRACT: As a biostable elastomer, the hydrophobicity of styrenic block copolymer (SBC) intensely limits its biomedical applications. In order to overcome such shortcoming, the SBC films were grafted with hyaluronic acid (HA) using a coupling agent. The surface chemistry of the modified films was examined by ATR-FTIR and XPS techniques, and the surface morphology was visually described by AFM. The biological performances of the HA-modified films were evaluated by a series of experiments, such as protein adsorption, platelet adhesion, and in vitro cytocompatibility. It was found that the HA-modified samples showed a low adhesiveness to fibroblast at the initial stage; however, it stimulated the growth of fibroblast. The L929 fibroblast growth presented a strong dependence on the molecular weight (MW) of HA. The samples modified with 17kDa HA exhibited the worst wettability and platelet adhesion, while providing the best results of supporting fibroblast proliferation.
Available from: Yao Wang
[Show abstract] [Hide abstract]
ABSTRACT: Angioplasty with stents is the most important method for the treatment of coronary artery disease (CAD). However, the drug-eluting stents (DES) which have been widely used nowadays have the increased risks of inflammatory reactions and late stent thrombosis (LST) due to the persistence of polymer coatings. To improve the bio-safety, a novel polymer-free composite drug-eluting coating composed of magnetic mesoporous silica nanoparticles (MMSNs) and carbon nanotubes (CNTs) is constructed using the electrophoretic deposition (EPD) method in this study. A crack-free two-layered coating with impressive "network" nanotopologies is successfully obtained by regulating the composition and structures. This nanostructured coating exhibits excellent mechanical flexibility and blood compatibility in vitro, and the drug-loading and release performance is satisfactory as well. The in vivo study shows that this composite coating has obvious advantages of rapid endothelialization due to its unique 3D nanostructured topologies in comparison with the commercial polymer-coated DES. This study is aimed to provide new ideas and reliable data to design novel functional coatings which could accelerate the re-endothelialization process and avoid inflammatory reactions, thus improving the in vivo bio-safety of DES.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.